sur VALBIOTIS (EPA:ALVAL)
Valbiotis Expands in the Middle East with Qatar Distribution Deal
French laboratory Valbiotis has announced an exclusive distribution agreement with Al Danah Medical Company in Qatar. This deal marks another milestone in Valbiotis' expansion in the Middle East. Al Danah, a leader in Qatar's healthcare and nutrition sector, will handle the launch of four Valbiotis products, including ValbiotisPRO® and Steadrive®.
The partnership foresees product registration, distribution, and promotion handled by Al Danah. Their market knowledge should facilitate successful entry into the Qatari market, where cardiometabolic health issues are prevalent. Expected revenues are anticipated as early as 2027.
This move aligns with Valbiotis' international strategy, following recent deals in Asia and the Middle East. Sébastien Peltier, CEO, highlights Qatar's rapid healthcare sector growth and demand for preventive solutions as driving factors for the agreement's potential success.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS